Literature DB >> 22589246

A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.

Selma M Soyal1, Thomas K Felder, Simon Auer, Penelope Hahne, Hannes Oberkofler, Anke Witting, Markus Paulmichl, G Bernhard Landwehrmeyer, Patrick Weydt, Wolfgang Patsch.   

Abstract

PGC-1α has been implicated in the pathogenesis of neurodegenerative disorders. Several single-nucleotide polymorphisms (SNPs) located in two separate haplotype blocks of PPARGC1A have shown associations with Huntington's disease (HD) and Parkinson's disease, but causative SNPs have not been identified. One SNP (rs7665116) was located in a highly conserved 233 bp region of intron 2. To determine whether rs7665116 is located in an alternative exon, we performed 5'-RLM-RACE from exon 3 and discovered multiple new transcripts that initiated from a common novel promoter located 587 kb upstream of exon 2, but did not contain the conserved region harboring rs7665116. Using real-time polymerase chain reaction, RNase protection assays and northern blotting, we show that the majority of these transcripts are brain specific and are at least equally or perhaps more abundant than the reference sequence PPARGC1A transcripts in whole brain. Two main transcripts containing independent methionine start codons encode full-length brain-specific PGC-1α proteins that differ only at their N-termini (NTs) from PGC-1α, encoded by the reference sequence. Additional truncated isoforms containing these NTs that are similar to NT-PGC-1α exist. Other transcripts may encode potential dominant negative forms, as they are predicted to lack the second LXXLL motif that serves as an interaction site for several nuclear receptors. Furthermore, we show that the new promoter is active in neuronal cell lines and describe haplotypes encompassing this region that are associated with HD age of onset. The discovery of such a large PPARGC1A genomic locus and multiple isoforms in brain warrants further functional studies and may provide new tissue-specific targets for treating neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589246     DOI: 10.1093/hmg/dds177

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  43 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  Metabolism in HD: still a relevant mechanism?

Authors:  Wenzhen Duan; Mali Jiang; Jing Jin
Journal:  Mov Disord       Date:  2014-08-13       Impact factor: 10.338

3.  Potential roles of PINK1 for increased PGC-1α-mediated mitochondrial fatty acid oxidation and their associations with Alzheimer disease and diabetes.

Authors:  Joungil Choi; Avinash Ravipati; Vamshi Nimmagadda; Manfred Schubert; Rudolph J Castellani; James W Russell
Journal:  Mitochondrion       Date:  2014-09-23       Impact factor: 4.160

4.  mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease.

Authors:  Rita Török; Júlia Anna Kónya; Dénes Zádori; Gábor Veres; Levente Szalárdy; László Vécsei; Péter Klivényi
Journal:  Cell Mol Neurobiol       Date:  2014-10-16       Impact factor: 5.046

5.  Overexpression of PGC-1α Influences Mitochondrial Signal Transduction of Dopaminergic Neurons.

Authors:  Qinyong Ye; Wanling Huang; Dongzhu Li; Erwang Si; Juhua Wang; Yingqing Wang; Chun Chen; Xiaochun Chen
Journal:  Mol Neurobiol       Date:  2015-07-04       Impact factor: 5.590

Review 6.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

Review 7.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

Review 8.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

9.  PGC-1α regulation of mitochondrial degeneration in experimental diabetic neuropathy.

Authors:  Joungil Choi; Krish Chandrasekaran; Tatsuya Inoue; Anjaneyulu Muragundla; James W Russell
Journal:  Neurobiol Dis       Date:  2014-01-11       Impact factor: 5.996

10.  A novel PGC-1α isoform in brain localizes to mitochondria and associates with PINK1 and VDAC.

Authors:  Joungil Choi; Vera Venkatanaresh Kumar Batchu; Manfred Schubert; Rudolph J Castellani; James W Russell
Journal:  Biochem Biophys Res Commun       Date:  2013-05-17       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.